Amyloid beta protein in plasma from patients with sporadic Alzheimer's disease.
Fibrillar amyloid beta protein (A beta) deposition is increased in the brains of patients with Alzheimer's disease (AD), and is manifested as senile plaques (SPs) and congophilic angiopathy (CA). A beta 40 and A beta 42(43), two chief species of A beta, are documented in SPs and CA, as well as in cerebrospinal fluid (CSF) and cell culture media. A beta 42(43) is the major component of diffuse plaques, the earliest form of SPs. Thus, we hypothesized that determination of the amount of A beta 42(43) in CSF or plasma might provide a diagnostic laboratory test for AD. We measured amounts of different A beta species in plasma from 28 patients with sporadic probable AD, 40 age-matched neurologic patients without dementia and 25 age-matched normal controls using enzyme-linked immunosorbent assays (ELISAs). Plasma concentrations of A beta 1-40 and A beta 1-42(43) did not significantly differ among these groups. These findings suggest the unlikelihood that plasma A beta assays would be useful as a diagnostic tool for AD.
Tamaoka
A
A
Department of Neurology, University of Tsukuba, Ibaraki, Japan.
Fukushima
T
T
Sawamura
N
N
Ishikawa
K
K
Oguni
E
E
Komatsuzaki
Y
Y
Shoji
S
S
D000368:Aged; D000369:Aged, 80 and over; D000544:Alzheimer Disease / Q000097:blood*; D016229:Amyloid beta-Peptides / Q000097:blood*; D004797:Enzyme-Linked Immunosorbent Assay; D005215:Fasting; D006801:Humans; D008875:Middle Aged; D010446:Peptide Fragments / Q000097:blood
D016229:Amyloid beta-Peptides; D010446:Peptide Fragments